Immunoglobulin al proteases (iga1 proteases), method of gene-technologically producing this type of enzyme and vaccines containing the enzymes and fragments thereof for immunizingagainst bacterial meningitis and other diseases caused by iga1 protease-producing bacteria
CA 2049984 A1 · Owner: Kilian, Mogens · Inventors: Kilian, Mogens; Poulsen, Knud
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Secretion of IgA1 proteases is a characteristic of Haemophilus influenzae and several other bacterial pathogens causing infectious diseases, including meningitis. Indirect evidence suggests that the proteases are important virulence factors. The iga gene encoding IgA1 protease, especially that from H. influenzae serotype b has been cloned into Escherichia coli in which the recombinant iga gene was expressed and the resulting protease secreted. Sequencing a part of a 7.5 kb DNA fragment containing the iga gene revealed a large open reading frame (ORF) with a strongly biased codon usage and having the potential of encoding a protein of 1541 amino acids and a molecular mass of 169 kd. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 16, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 16, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 16, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.